bFGF (119-126)

Name: bFGF (119-126)
Brand: MedChemExpress
SKU: HY-P5321
Rating: 5.0 (5 reviews)

Cat. No.: HY-P5321 Purity: 99.93%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

bFGF (119-126) is a ligand of bFGF. The complex formed by bFGF (119-126) and bFGF can bind to FGFR1, while inhibiting the bFGF-FGFR1 interaction, FGFR1 phosphorylation and downstream signaling pathways. Therefore, bFGF (119-126) induces cell apoptosis and inhibits cell proliferation, migration, angiogenesis and metastasis. When conjugated with a carrier, bFGF (119-126) enhances cellular uptake via FGFR-mediated endocytosis and serves as an effective FGFR-targeted ligand. When used in combination with ultrasound and Doxorubicin (HY-15142A), bFGF (119-126) significantly enhances the inhibitory effect on tumors. bFGF (119-126) is applicable to research related to lung cancer, breast cancer, glioblastoma and ovarian cancer.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

bFGF (119-126) Chemical Structure

CAS No. : 152051-61-1

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

5 Publications Citing Use of MCE bFGF (119-126)

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

FITC-bFGFp-BSA, a peptide derived from bFGF (119-126), at 50 μg/mL for 2 h, is significantly internalized by NIH3T3 cells with high FGFRs expression, and this internalization effect is significantly inhibited by excess free bFGFp^[2].
Cyclic peptide BGF1 derived from bFGF (119-126) (0.22~1.8 mM; 48 h) dose-dependently inhibits the proliferation of HUVECs, 4T1, U87 and SKOV3 cells induced by 20 ng/mL bFGF, with IC₅₀ values of 1.09 μM, 1.27 mM, 0.65 μM and 0.18 μM for different cells, respectively. The linear peptide at 3 mM shows no such proliferation-inhibiting effect^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	NIH3T3 mouse embryonic fibroblast cells
Concentration:	0.1 μM, 1.0 μM free bFGFp; 0.72 μg/mL, 7.2 μg/mL bFGFp-BSA; 4 μM, 40 μM bFGFp-modified liposomes
Incubation Time:	72 h
Result:	Neither the free bFGFp, bFGFp-BSA conjugate, nor bFGFp-modified liposomes altered the proliferation and viability of NIH3T3 cells, regardless of the presence or absence of 1 nM bFGF in the culture medium.

In Vivo

Cyclic peptide BGF1 derived from bFGF (119-126) (2 mg/kg; i.p.; once daily; 3-week administration cycle) significantly inhibits tumor growth in the subcutaneous xenograft model of 4T1 breast cancer in 6-8-week-old female BALB/c mice, with a tumor growth inhibition rate of approximately 14% after 34 days of administration, and does not cause body weight loss in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6–8 weeks-old female BALB/c mice with 4T1 murine mammary carcinoma subcutaneous metastatic tumor model, transplanted with 4T1 tumor fragments subcutaneously on the right flank, treatment initiated when tumor volume reached ~150 mm³ (14 days after tumor implantation)^[3]
Dosage:	Cyclic peptide BGF1 at 2 mg/kg and 10 mg/kg, linear peptide BGF2 at 2 mg/kg and 10 mg/kg
Administration:	all via intraperitoneal (i.p.) injection daily for 3 weeks; Avastin at 5 mg/kg via intravenous (i.v.) injection once every 14 days (total 2 times); PBS as vehicle control via daily i.p. injection. All agents were dissolved in phosphate-buffered saline
Result:	The 10 mg/kg BGF1 treatment group achieved ~70% tumor growth inhibition on day 34 after implantation, which was significantly more effective than the Avastin group, while the 2 mg/kg BGF1 group showed ~14% tumor growth inhibition. Neither 2 mg/kg nor 10 mg/kg of linear peptide BGF2 showed significant inhibitory effect on tumor growth compared with the PBS control group. All mice in the 10 mg/kg BGF1 group survived until the end of the experiment, while the mortality rate was 29% in the PBS group, 86% in the Avastin group, 29% in the 2 mg/kg BGF1 group, and 29% in the BGF2 groups. Mice in the BGF1 treatment groups gained weight during the experiment, while the Avastin group showed significant weight loss.

Molecular Weight

993.16

Formula

C₄₄H₇₆N₁₄O₁₂

CAS No.

152051-61-1

Appearance

Solid

Color

White to off-white

Sequence

Lys-Arg-Thr-Gly-Gln-Tyr-Lys-Leu

Sequence Shortening

KRTGQYKL

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (100.69 mM)

DMSO : 50 mg/mL (50.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.0069 mL	5.0344 mL	10.0689 mL
5 mM	0.2014 mL	1.0069 mL	2.0138 mL
10 mM	0.1007 mL	0.5034 mL	1.0069 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.93%

Select Batch:

Data Sheet (275 KB) SDS (252 KB)

COA (240 KB) RP-HPLC (247 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Terada T, et al. Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. J Drug Target. 2006;14(8):536-545. [Content Brief]

[2]. Wu Y, et al. Preparation and antitumor activity of bFGF-mediated active targeting doxorubicin microbubbles. Drug Dev Ind Pharm. 2013;39(11):1712-1719. [Content Brief]

[3]. Allahmoradi H, et al. Anti-tumor and anti-metastatic activity of the FGF2 118-126 fragment dependent on the loop structure. Biochem J. 2022;479(12):1285-1302. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	1.0069 mL	5.0344 mL	10.0689 mL	25.1722 mL
	5 mM	0.2014 mL	1.0069 mL	2.0138 mL	5.0344 mL
	10 mM	0.1007 mL	0.5034 mL	1.0069 mL	2.5172 mL
	15 mM	0.0671 mL	0.3356 mL	0.6713 mL	1.6781 mL
	20 mM	0.0503 mL	0.2517 mL	0.5034 mL	1.2586 mL
	25 mM	0.0403 mL	0.2014 mL	0.4028 mL	1.0069 mL
	30 mM	0.0336 mL	0.1678 mL	0.3356 mL	0.8391 mL
	40 mM	0.0252 mL	0.1259 mL	0.2517 mL	0.6293 mL
	50 mM	0.0201 mL	0.1007 mL	0.2014 mL	0.5034 mL
H₂O	60 mM	0.0168 mL	0.0839 mL	0.1678 mL	0.4195 mL
	80 mM	0.0126 mL	0.0629 mL	0.1259 mL	0.3147 mL
	100 mM	0.0101 mL	0.0503 mL	0.1007 mL	0.2517 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

bFGF (119-126) Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

bFGF (119-126)152051-61-1FGFRFibroblast growth factor receptorovarian carcinomaFGFR1angiogenesisglioblastomaNIH3T3 cellmetastasisapoptosislung cancermammary carcinomabFGFInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

bFGF (119-126)

Customer Review

bFGF (119-126) Related Antibodies

5 Publications Citing Use of MCE bFGF (119-126)

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

bFGF (119-126) Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

bFGF (119-126) Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report